share_log

Despite Shrinking by US$343m in the Past Week, HealthEquity (NASDAQ:HQY) Shareholders Are Still up 40% Over 3 Years

Despite Shrinking by US$343m in the Past Week, HealthEquity (NASDAQ:HQY) Shareholders Are Still up 40% Over 3 Years

儘管在過去一週萎縮了3.43億美元,但HealthEquity(納斯達克股票代碼:HQY)的股東在3年內仍上漲了40%
Simply Wall St ·  2023/10/26 13:11

By buying an index fund, investors can approximate the average market return. But many of us dare to dream of bigger returns, and build a portfolio ourselves. For example, HealthEquity, Inc. (NASDAQ:HQY) shareholders have seen the share price rise 40% over three years, well in excess of the market return (17%, not including dividends).

通過購買指數基金,投資者可以接近平均市場回報。但我們中的許多人都敢於夢想更高的回報,並自己建立投資組合。例如,HealthEquity公司納斯達克(Sequoia Capital:HQY)股東看到股價在三年內上漲了40%,遠遠超過了市場回報率(17%,不包括股息)。

Although HealthEquity has shed US$343m from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.

儘管HealthEquity本週市值縮水3.43億美元,但讓我們看看其較長期的基本面趨勢,看看它們是否推動了回報。

Check out our latest analysis for HealthEquity

查看我們對HealthEquity的最新分析

While HealthEquity made a small profit, in the last year, we think that the market is probably more focussed on the top line growth at the moment. As a general rule, we think this kind of company is more comparable to loss-making stocks, since the actual profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.

雖然HealthEquity在去年實現了小幅盈利,但我們認為,目前市場可能更關注營收增長。一般來說,我們認為這類公司更類似於虧損股票,因為實際利潤如此之低。要讓股東有信心一家公司的利潤將大幅增長,它必須增加收入。

HealthEquity's revenue trended up 8.4% each year over three years. That's pretty nice growth. The share price gain of 12% per year shows that the market is paying attention to this growth. Of course, valuation is quite sensitive to the rate of growth. Of course, it's always worth considering funding risks when a company isn't profitable.

HealthEquity的收入在過去三年裡以每年8.4%的速度增長。這是一個相當不錯的增長。股價每年12%的漲幅表明市場正在關注這一增長。當然,估值對增長率相當敏感。當然,當一家公司沒有盈利時,考慮融資風險總是值得的。

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

該公司的收入和收益(隨著時間的推移)如下圖所示(點擊查看具體數位)。

earnings-and-revenue-growth
NasdaqGS:HQY Earnings and Revenue Growth October 26th 2023
NasdaqGS:2023年10月26日HQY收益和收入增長

HealthEquity is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. So it makes a lot of sense to check out what analysts think HealthEquity will earn in the future (free analyst consensus estimates)

HealthEquity為投資者所熟知,許多聰明的分析師曾試圖預測未來的利潤水準。因此,看看分析師認為HealthEquity未來的收益是多少是很有意義的(免費分析師共識估計)

A Different Perspective

不同的視角

HealthEquity shareholders are down 2.4% for the year, but the market itself is up 9.9%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, longer term shareholders are suffering worse, given the loss of 4% doled out over the last five years. We'd need to see some sustained improvements in the key metrics before we could muster much enthusiasm. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 1 warning sign for HealthEquity that you should be aware of.

HealthEquity股東今年以來下跌了2.4%,但市場本身上漲了9.9%。然而,請記住,即使是最好的股票,在12個月的時間裡,有時也會表現遜於市場。不幸的是,考慮到過去五年4%的損失,長期股東的損失更大。我們需要在關鍵指標上看到一些持續的改善,然後我們才能調動起太多的熱情。雖然值得考慮市場狀況對股價可能產生的不同影響,但還有其他更重要的因素。例如,我們已經確定HealthEquity的1個警告標誌這一點你應該知道.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

如果你更願意看看另一家公司--一家財務狀況可能更好的公司--那麼不要錯過這一點免費已證明自己能夠實現盈利增長的公司名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論